Top 6 Therapeutic Companies to Look out for Acute Renal Failure (Acute Kidney Injury)

Top 5 Therapeutic Companies to Look out for Acute Renal Failure (Acute Kidney Injury)

According to Report forecasts, total incident population of Acute Kidney Injury in 7 major markets was estimated to be 1.5 Million in 2016.

Acute kidney disease has consistently been associated with increased morbidity and mortality and multiple studies, as well as a recent meta-analysis, have demonstrated worse outcomes in the case of hospitalized patients.

Acute renal failure (ARF) is characterized by azotemia that progresses over several hours or days, with or without oliguria. Acute kidney injury (AKI), formerly called acute renal failure (ARF), is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes.

ARF is further sub-classified into three stages: Stage-I, Stage- II and Stage- III. Out of the three main stages, Stage II ARF has the highest percentage of incidence. Based on DelveInsight’s analysis, approximately 36% of Acute Renal Failure patients suffered Stage II ARF, 35% suffered Stage III ARF and 28% suffered Stage I ARF in 2016.

Incident Cases of Acute Renal Failure (2016-2027)

According to report’s assessment for the Market Size suggests that owing to the launch of upcoming therapies, an increase of the Global market size (7MM and Rest of the world) of Acute Renal Failure during the study period (2016-2027) can be observed. Also, as per DelveInsight’s estimation, the 7MM Market Size of Acute Renal Failure is expected to reach up to USD 8.7 billion in the year 2027.

Market Size of ARF (2016-2027)

There is large windows of opportunity: to prevent AKI, to treat AKI after its onset, and to halt progression to ESRD. The pharmaceutical industry are investing on clinical trials conducted in the cardiovascular space, yet is little reluctant to enter the kidney market as the overall market is driven by monitoring system followed by transplantation with a very small therapeutic window. Some of the flaws in clinical trial design contributing to poor outcomes and potential strategies for designing clinical trials for AKI have been realized.

Many novel therapies are under the later phase of development targeting a better preventive and therapeutic approach. Few Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Products  given below:

ARF Sales by Therapies

Analysts estimate that the market is expected to show a significant rise, mainly attributed to the launch of emerging therapies in coming years.

Top 6 therapeutic companies to look out for Acute Renal Failure (Acute Kidney Injury)

1. Quark Pharma: QPI-1002, an siRNA targeting the p53 gene: clinical trials include a Phase I/ II study for the prevention of Delayed Graft Function (DGF) in deceased donor kidney transplant patients, and two Phase I studies in Acute Kidney Injury (AKI) following cardiac surgery. The drug has received Orphan Drug Designation from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and Fast Track designation by the FDA for the DGF indication.(Source: Company Website)

2. AM Pharma:AM‐Pharma B.V. focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, company got positive results from its adaptive Phase II study in 301 sepsis patients with Acute Kidney Injury (AKI), the largest therapeutic study in AKI to date.(Source: Company Website)

3.Angion Biomedica: BB3 is a small molecule with hepatocyte growth factor (HGF)-like activity that is entering Phase 3 clinical trials to limit delayed graft function in kidney transplant recipients, and entering Phase 2 clinical trials in cardiac surgery patients who develop acute kidney injury. (Source: Company Website)

4. LG Life Sciences: Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners. Besides, this drug has also been studied for the treatment of T2DM as monotherapy, in combination with metformin or other oral antidiabetic drugs and in T2DM with moderate-to-severe renal failure(Phase II/III Acute kidney injury).

5.Alloksys : Alloksys Life Sciences developed the therapeutic RESCAP® platform based on Alkaline Phosphatase (AP), a naturally occurring protein in the human body. RESCAP® further protects, maintains and restores integrity of physiological barriers, such as Kidney Glomerulus Barrier (KGB) Blood Brain Barrier(BBB), Lung Alveolar Barrier(LAB), Gut Barrier (GB) and Placental Barrier (PB).(Source: Company Website)

6. Exponential Biotherapeutics: EBI’s lead product suppresses the exaggerated immune response and therefore has the potential to prevent a range of severe inflammatory disorders. The most important indication is acute kidney injury (AKI).After successful development of EBI’s lead product (EA-230) for AKI and irradiation damage, EBI’s pipeline provides a path forward for the development of new and promising critical care therapies for multiple organ damage related to systemic inflammatory responses.(Source: Company Website)

Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2027

Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2027

 

Browse Report

About The Author

Clients Who Trust Us

Need tailor made market research solution? We can help you with that too.

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected